ETF Managers Group LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 31.1% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,363 shares of the company’s stock after selling 3,327 shares during the period. ETF Managers Group LLC’s holdings in Johnson & Johnson were worth $979,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in JNJ. Austin Private Wealth LLC grew its position in shares of Johnson & Johnson by 2.5% in the 1st quarter. Austin Private Wealth LLC now owns 2,830 shares of the company’s stock worth $371,000 after buying an additional 68 shares during the period. Sun Life Financial INC boosted its stake in Johnson & Johnson by 2.5% during the first quarter. Sun Life Financial INC now owns 2,758 shares of the company’s stock worth $362,000 after acquiring an additional 68 shares in the last quarter. Dumont & Blake Investment Advisors LLC grew its holdings in Johnson & Johnson by 0.3% in the fourth quarter. Dumont & Blake Investment Advisors LLC now owns 20,796 shares of the company’s stock worth $3,033,000 after purchasing an additional 71 shares during the period. DE Burlo Group Inc. grew its holdings in Johnson & Johnson by 3.9% in the fourth quarter. DE Burlo Group Inc. now owns 1,871 shares of the company’s stock worth $273,000 after purchasing an additional 71 shares during the period. Finally, Modus Advisors LLC increased its stake in shares of Johnson & Johnson by 2.0% during the first quarter. Modus Advisors LLC now owns 3,666 shares of the company’s stock valued at $481,000 after purchasing an additional 73 shares in the last quarter. 68.51% of the stock is currently owned by institutional investors.
In other Johnson & Johnson news, Director William D. Perez acquired 500 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was purchased at an average price of $127.69 per share, with a total value of $63,845.00. Following the transaction, the director now directly owns 16,030 shares in the company, valued at approximately $2,046,870.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.27% of the company’s stock.
Shares of JNJ traded up $1.69 during trading hours on Wednesday, hitting $147.65. The stock had a trading volume of 1,064,067 shares, compared to its average volume of 9,785,549. The firm has a market capitalization of $388.08 billion, a PE ratio of 19.31, a PEG ratio of 3.20 and a beta of 0.70. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.31 and a quick ratio of 1.05. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The stock has a fifty day moving average price of $148.86 and a 200 day moving average price of $143.59.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.27. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The business had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. During the same period in the previous year, the company posted $2.10 EPS. The business’s quarterly revenue was up 3.3% compared to the same quarter last year. As a group, analysts anticipate that Johnson & Johnson will post 7.68 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were given a $1.01 dividend. The ex-dividend date was Friday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. This represents a $4.04 annualized dividend and a yield of 2.74%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
Several analysts recently weighed in on JNJ shares. Stifel Nicolaus upped their price target on Johnson & Johnson from $140.00 to $155.00 and gave the stock a “hold” rating in a research note on Wednesday, April 15th. Bank of America upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price target for the company from $150.00 to $175.00 in a report on Wednesday, April 22nd. Credit Suisse Group reiterated a “buy” rating and issued a $161.00 price target on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Citigroup raised their price objective on shares of Johnson & Johnson from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, April 15th. Finally, SVB Leerink dropped their target price on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $163.47.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.